查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017053

傷口生物製劑市場：全球市場按產品類型、應用、最終用戶和分銷管道分類的預測 - 2026-2032 年

Wound Biologics Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，傷口生物製劑市場價值將達到 3.9182 億美元，到 2026 年將成長至 4.5269 億美元，到 2032 年將達到 9.9077 億美元，複合年成長率為 14.17%。

主要市場統計數據
基準年 2025 3.9182億美元
預計年份：2026年 4.5269億美元
預測年份 2032 9.9077億美元
複合年成長率 (%) 14.17%

一份全面的總結，說明了目前影響傷口生物製劑領域的技術促進因素、臨床重點和策略動機。

由於科學進步、治療路徑的改變以及醫療保健相關人員日益成長的商業性興趣，傷口生物製劑領域正在迅速發展。本文概述了該領域的現狀，闡明了關鍵治療方法的分類，並論證了為何臨床醫生、醫院系統和生命科學投資者現在必須對傷口生物製劑療法給予策略關注。

技術創新、監管政策的明確性以及醫療服務體系的改革，是如何重塑傷口生物製劑領域的競爭格局和推廣路徑的？

隨著科學創新、監管進步和醫療服務體系改革的融合，傷口生物製劑領域正經歷變革性的轉變。在產品層面，支架工程、精準生長因子配方和自體血小板衍生成分的改進正在提升治療的特異性和便利性。這些技術進步與監管途徑相輔相成，監管途徑日益認可生物製劑相對於傳統外用藥物的獨特風險獲益比，從而在安全性和生產控制措施健全的情況下，為生物製劑的臨床應用鋪平了道路。

系統性評估近期關稅措施對傷口生物製劑領域採購決策、供應鏈韌性和採購行為的影響。

2025年實施的關稅上調對傷口生物製劑的採購、生產策略和採購慣例產生了顯著的下游影響。對進口原料、成品和生物製藥組件徵收的關稅增加了接收成本，促使製造商重新評估其組件採購，並凸顯了近岸外包和供應鏈多元化的重要性。因此，契約製造和供應商被迫重新評估其成本會計模式和庫存策略，以在不中斷臨床試驗點供應的情況下維持獲利能力。

將產品模式、臨床適應症、醫療保健環境和分銷管道與策略商業化機會聯繫起來的詳細細分分析。

詳細的市場細分揭示了產品、應用、終端用戶和分銷管道等各個類別中清晰的價值來源、臨床應用案例和商業化路徑。按產品類型分類，治療領域包括膠原蛋白、生長因子、血小板衍生成分和皮膚替代物。在膠原蛋白製劑中，牛、馬源和豬源膠原蛋白的免疫抗原性和操作特性各不相同，這會影響臨床醫生的選擇和監管策略。生長因子類別包括表皮生長因子、纖維母細胞生長因子、血小板衍生生長因子和血管內皮生長因子，每種生長因子都有獨特的作用機制，指南適應症的選擇和聯合治療。血小板衍生製劑，以濃縮血小板纖維蛋白和濃縮血小板血漿為代表，屬於自體，其獨特之處在於能夠作為臨床干預手段改變治療過程。皮膚替代物包括生物真皮、複合真皮和合成真皮結構，反映了生物整合和生產一致性之間的權衡。

區域比較分析揭示了管理體制、支付方優先事項和醫療保健基礎設施如何決定全球市場的採用路徑。

區域趨勢正在以不同的方式影響美洲、歐洲、中東和非洲以及亞太市場的技術採納、報銷政策和供應鏈策略。在美洲，完善的臨床基礎設施和成熟的創傷護理專業網路促進了新型生物製劑的早期應用，這些製劑展現出臨床差異化優勢和營運效率。此外，這些市場優先考慮透過真實世界研究和整合式護理路徑來獲取證據，從而催生了對能夠展現以患者為中心的療效的產品的需求。

評估競爭定位和策略性舉措，以推動創新通路、生產規模和證據產生能力的差異化。

傷口生物製劑領域的競爭格局由差異化的科學平台、生產能力和實證醫學證據所構成。領先的技術開發商正投資於下一代支架化學、多因子生長因子組合和標準化自體組織處理系統，而契約製造和元件供應商則在不斷提升自身能力，以滿足生物製劑嚴格的品質和無菌要求。策略性措施還包括與臨床專家和產品開發人員夥伴關係，共同設計符合實際臨床工作流程的操作和應用方案。

為製造商和供應商制定具體和優先行動，以協調創新重點、加強供應鏈，並加速傷口生物製劑領域臨床機構和保險公司的採用。

產業領導者應採取一系列協調一致的措施，在有效管理商業性和營運風險的同時，充分利用科學進步。首先，研發重點應與醫療機構的實際需求相契合，開發出符合醫院、創傷護理中心、門診手術中心和居家照護機構在處理、儲存和應用方面實際要求的產品。其次，透過採購多元化、近岸外包以及策略性庫存管理政策，增強供應鏈韌性，進而降低貿易政策波動和物流中斷帶來的風險。

透明的混合方法研究框架結合了對臨床醫生的訪談、對技術文件的審查以及供應鏈分析，檢驗了具有臨床和商業性意義的研究結果。

本研究採用混合方法，結合一手定性訪談、二手文獻綜述、產品技術文件和供應鏈圖譜，對傷口生物製劑領域進行了嚴謹而實用的分析。一手資訊包括對醫院臨床醫生、創傷護理專家、採購經理、法規專家和生產合作夥伴的結構化訪談，旨在了解實際應用模式、未滿足的臨床需求和採購考量。這些觀點與法規指南、同行評審的科學文獻和產品標籤資訊進行交叉比對，以檢驗作用機制和安全性特徵。

這項具有前瞻性的綜合分析強調，涵蓋研發、供應鏈和市場准入的整合策略對於在傷口生物製劑領域獲得永續的競爭優勢至關重要。

總之，傷口生物製劑領域正處於一個轉折點，科學進步、變革性護理模式和商業性壓力在此交匯，既帶來了機遇，也帶來了挑戰。兼具強大生物功能、實用臨床應用性和可靠供應的技術將很快被採用。同時，不斷變化的貿易政策和報銷預期要求製造商在產品生產地點和方式、定價以及證據呈現等方面採取策略性方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 傷口生物製劑市場：依產品類型分類

  • 膠原蛋白
    • 牛膠原蛋白
    • 馬膠原膠原蛋白
    • 豬膠原膠原蛋白
  • 生長因子
    • 表皮生長因子
    • 纖維母細胞生長因子
    • 血小板衍生生長因子
    • 血管內皮生長因子
  • 血小板衍生製劑
    • 血小板濃縮纖維蛋白
    • 富血小板血漿
  • 皮膚替代材料
    • 活體真皮
    • 複合真皮
    • 合成真皮

第9章 傷口生物製劑市場：依應用領域分類

  • 急性傷口
  • 燒傷
    • 二度燒傷
    • 三度燒傷
  • 慢性傷口
    • 糖尿病足潰瘍
    • 壓瘡
    • 下肢靜脈潰瘍
  • 手術傷口

第10章 傷口生物製劑市場：依最終使用者分類

  • 門診手術中心
  • 居家照護
  • 醫院
  • 創傷護理中心

第11章 傷口生物製劑市場：依通路分類

  • 離線
  • 線上

第12章 傷口生物製劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 傷口生物製劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 傷口生物製劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國傷口生物製劑市場

第16章：中國傷口生物製劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • Alliqua BioMedical, Inc.
  • Avita Medical Ltd.
  • Celularity, Inc.
  • CollPlant Biotechnologies Ltd.
  • Integra LifeSciences Holdings Corporation
  • MiMedx Group, Inc.
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Smith & Nephew plc
Product Code: MRR-0315DDADCE4B

The Wound Biologics Market was valued at USD 391.82 million in 2025 and is projected to grow to USD 452.69 million in 2026, with a CAGR of 14.17%, reaching USD 990.77 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 391.82 million
Estimated Year [2026] USD 452.69 million
Forecast Year [2032] USD 990.77 million
CAGR (%) 14.17%

A comprehensive orienting summary that explains current technological drivers, clinical priorities, and strategic motivations shaping the wound biologics sector

The wound biologics landscape is rapidly evolving, driven by scientific progress, changing care pathways, and heightened commercial interest across healthcare stakeholders. This introduction distills the field's contemporary contours, clarifies the principal classes of therapeutic modalities, and frames why strategic attention to biologic wound therapies is now imperative for clinicians, hospital systems, and life sciences investors.

Recent advances in biomaterials, regenerative medicine, and point-of-care delivery have shifted wound care from purely symptomatic management to targeted biological intervention. As a result, clinicians seek products that integrate scaffold performance, growth factor activity, and autologous preparations with clear handling and safety profiles. Meanwhile, health systems and ambulatory providers are recalibrating procurement and care pathways to prioritize therapies that reduce complications, shorten healing times, and optimize resource utilization. This introduction sets the context for the subsequent sections by outlining key technological trajectories, reimbursement considerations, and cross-stakeholder expectations that together shape near-term commercial and clinical decision-making.

How converging technical innovations, regulatory clarity, and care delivery reforms are reshaping competitive dynamics and adoption pathways across wound biologics

The wound biologics sector is experiencing transformative shifts that recombine scientific innovation, regulatory evolution, and care delivery reforms. At the product level, improvements in scaffold engineering, precision growth factor formulations, and autologous platelet derivatives are enhancing therapeutic specificity and usability. These technological advances are complemented by regulatory pathways that increasingly recognize the distinct risk-benefit profiles of biologics versus traditional topical agents, allowing clearer pathways to clinical adoption when safety and manufacturing controls are robust.

Concurrently, delivery models are changing: hospitals and wound care centers are integrating biologic therapies earlier in care algorithms, while ambulatory surgical centers and home care providers are adopting streamlined products designed for lower-complexity settings. Payment models and value-based contracting are nudging manufacturers to demonstrate real-world effectiveness and predictable outcomes. Taken together, these shifts create a more competitive environment in which clinical differentiation, supply chain resilience, and evidence generation are decisive. Strategic alignment across R&D, regulatory affairs, and commercial functions will determine which organizations capitalize on these structural changes.

Evaluating the systemic consequences of recent tariff actions on sourcing decisions, supply chain resilience, and procurement behaviors within wound biologics

The introduction of elevated tariff measures in 2025 has created material downstream effects across sourcing, manufacturing strategy, and procurement practices for wound biologics. Tariffs applied to imported raw materials, finished devices, and biologic components have increased landed costs and prompted manufacturers to reassess component sourcing, with a renewed emphasis on nearshoring and supply base diversification. In turn, contract manufacturers and suppliers have needed to revisit costing models and inventory strategies to preserve margins while ensuring uninterrupted supply to clinical customers.

These trade policy shifts have also influenced clinical adoption patterns indirectly. Procurement teams within hospitals and wound care centers are placing greater weight on total cost of ownership and supply certainty when evaluating supplier partnerships; products that offer simplified handling and reduced dependence on imported ancillary materials gain a comparative advantage. Further, some innovators are accelerating localized manufacturing investments and technology transfers to mitigate tariff exposure and shorten lead times. Overall, the 2025 tariff environment has elevated supply chain strategy to a core commercial imperative, making resilience, flexibility, and cost transparency critical for sustained market participation.

A granular segmentation analysis linking product modalities, clinical indications, care settings, and distribution channels to strategic commercialization opportunities

Detailed segmentation illuminates distinct value drivers, clinical use cases, and commercial pathways across product, application, end user, and distribution channel categories. Based on product type, the therapeutic set includes Collagen, Growth Factors, Platelet Derivatives, and Skin Substitutes; within Collagen formulations, bovine, equine, and porcine sources present differing immunogenic and handling profiles that affect clinician preference and regulatory strategy. The Growth Factors category encompasses epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor, each with unique mechanisms that guide indication targeting and combination approaches. Platelet Derivatives are represented by platelet-rich fibrin and platelet-rich plasma, which are distinctive for being autologous, point-of-care interventions that shift procedural workflows. Skin Substitutes include biological dermal, composite dermal, and synthetic dermal constructs, with trade-offs between biological integration and manufacturing consistency.

Turning to application-based segmentation, acute wounds, burns, chronic wounds, and surgical wounds define different clinical endpoints and evidence expectations; burns subdivide into second-degree and third-degree presentations while chronic wounds include diabetic foot ulcers, pressure ulcers, and venous leg ulcers, each requiring tailored therapeutic strategies. End-user segmentation spans ambulatory surgical centers, home care, hospitals, and wound care centers, a mix that underscores varying procurement cycles, clinician competencies, and procedural settings. Finally, distribution channels are broadly offline and online, the former encompassing traditional clinical distributors and hospital supply chains and the latter growing through direct-to-provider and institutional e-commerce platforms. Integrating these segment dimensions reveals where clinical need, operational feasibility, and commercial scale align to favor specific technologies and go-to-market approaches.

Comparative regional intelligence revealing how regulatory regimes, payer priorities, and care infrastructure determine pathways to adoption across global markets

Regional dynamics shape technology adoption, reimbursement policy, and supply chain strategy in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, strong clinical infrastructure and established wound care specialty networks favor early adoption of novel biologics that demonstrate clinical differentiation and operational efficiency. These markets also prioritize evidence generation through real-world studies and integrated care pathways, creating demand for products that can show patient-centric outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and payer systems require localized market access strategies, with some territories emphasizing cost-effectiveness and centralized procurement and others relying on specialist centers to champion innovations. The Asia-Pacific region exhibits rapid expansion in clinical capacity and manufacturing investment, fostering both demand and the potential for regional production scale. Across these geographies, differences in clinician training, reimbursement levers, and supply chain infrastructure mean that manufacturers must adopt region-specific evidence plans, distribution partnerships, and regulatory strategies to realize adoption at scale.

An assessment of competitive positioning and strategic moves that drive differentiation across innovation pipelines, manufacturing scale, and evidence-generation capabilities

Competitive dynamics within wound biologics are defined by differentiated science platforms, manufacturing capabilities, and evidence portfolios. Leading technology developers are investing in next-generation scaffold chemistries, multi-factor growth factor combinations, and standardized autologous processing systems, while contract manufacturers and component suppliers are scaling capabilities to meet stringent biologics quality and sterility demands. Strategic activity also includes partnerships between clinical leaders and product developers to co-design handling and application protocols that align with real-world workflows.

Moreover, go-to-market differentiation increasingly hinges on post-marketing data capture, real-world evidence generation, and health economic modeling that speak to payers and hospital purchasing. Some companies are prioritizing vertically integrated approaches to control supply chain risks, while others are forming alliances to expand distribution reach into ambulatory and home care channels. As market maturity advances, expect consolidation around integrated platforms that combine robust clinical outcomes with scalable manufacturing and reliable distribution footprints, thereby setting a higher bar for new entrants.

Concrete, prioritized actions for manufacturers and providers to align innovation priorities, fortify supply chains, and accelerate clinical and payer adoption in wound biologics

Industry leaders should adopt a coordinated set of actions to capitalize on scientific advances while managing commercial and operational risks. First, align R&D prioritization with care setting needs by developing products that meet the handling, storage, and application realities of hospitals, wound care centers, ambulatory surgical centers, and home care providers. Second, enhance supply chain resilience through diversified sourcing, nearshoring options, and strategic inventory policies that mitigate exposure to trade policy shifts and logistical disruptions.

Third, invest in rigorous clinical and health economic evidence that addresses payer concerns and facilitates pathway adoption; pragmatic trials and real-world registries can accelerate reimbursement conversations. Fourth, tailor regional market access plans that reflect local regulatory frameworks and procurement dynamics, ensuring that market entry sequences are optimized for reimbursement and clinician engagement. Finally, explore partnership models that bundle products with training, digital tracking, and outcome measurement to create differentiated value propositions that capture both clinical and economic stakeholders.

A transparent mixed-methods research framework combining clinician interviews, technical dossier review, and supply chain analysis to validate clinically and commercially relevant findings

This research synthesis draws on a mixed-methods approach that integrates primary qualitative interviews, secondary literature review, product technical dossiers, and supply chain mapping to construct a rigorous and actionable view of the wound biologics sector. Primary inputs include structured interviews with clinicians across hospital settings, wound care specialists, procurement leaders, regulatory experts, and manufacturing partners to capture real-world usage patterns, unmet clinical needs, and sourcing considerations. These perspectives were triangulated with regulatory guidance, peer-reviewed scientific literature, and product labeling information to validate mechanism-of-action claims and safety profiles.

In addition, supply chain analyses employed trade flow data, component sourcing reviews, and contract manufacturing assessments to illuminate tariff exposure and manufacturing risk. Segmentation frameworks were populated by mapping product characteristics to clinical indications and end-user workflows, and distribution channel analysis evaluated transactional friction points and digital adoption trends. Throughout, findings were cross-validated through iterative stakeholder feedback to ensure relevance and practical applicability for commercial and clinical decision-makers.

A forward-looking synthesis emphasizing the imperative for integrated strategies across R&D, supply chain, and market access to secure durable advantage in wound biologics

In conclusion, the wound biologics field stands at an inflection point where scientific progress, shifting care models, and commercial pressures converge to create both opportunity and complexity. Technologies that marry robust biological function with practical clinical handling and supply reliability will win early adoption. Concurrently, changes in trade policy and reimbursement expectations mean that manufacturers must be strategic about where and how they produce, price, and evidence their products.

Looking forward, organizations that integrate cross-functional planning-from R&D and regulatory to supply chain and market access-will be best positioned to capture durable value. Success will depend on demonstrating real-world outcomes, maintaining manufacturing and distribution resilience, and executing regionally nuanced commercialization strategies that reflect distinct payer and clinical landscapes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Wound Biologics Market, by Product Type

  • 8.1. Collagen
    • 8.1.1. Bovine Collagen
    • 8.1.2. Equine Collagen
    • 8.1.3. Porcine Collagen
  • 8.2. Growth Factors
    • 8.2.1. Epidermal Growth Factor
    • 8.2.2. Fibroblast Growth Factor
    • 8.2.3. Platelet Derived Growth Factor
    • 8.2.4. Vascular Endothelial Growth Factor
  • 8.3. Platelet Derivatives
    • 8.3.1. Platelet Rich Fibrin
    • 8.3.2. Platelet Rich Plasma
  • 8.4. Skin Substitutes
    • 8.4.1. Biological Dermal
    • 8.4.2. Composite Dermal
    • 8.4.3. Synthetic Dermal

9. Wound Biologics Market, by Application

  • 9.1. Acute Wounds
  • 9.2. Burns
    • 9.2.1. Second Degree Burns
    • 9.2.2. Third Degree Burns
  • 9.3. Chronic Wounds
    • 9.3.1. Diabetic Foot Ulcer
    • 9.3.2. Pressure Ulcer
    • 9.3.3. Venous Leg Ulcer
  • 9.4. Surgical Wounds

10. Wound Biologics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Wound Care Centers

11. Wound Biologics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Wound Biologics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Wound Biologics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Wound Biologics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Wound Biologics Market

16. China Wound Biologics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. Alliqua BioMedical, Inc.
  • 17.7. Avita Medical Ltd.
  • 17.8. Celularity, Inc.
  • 17.9. CollPlant Biotechnologies Ltd.
  • 17.10. Integra LifeSciences Holdings Corporation
  • 17.11. MiMedx Group, Inc.
  • 17.12. Molnlycke Health Care AB
  • 17.13. Organogenesis Inc.
  • 17.14. Smith & Nephew plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WOUND BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL WOUND BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GCC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 209. GCC WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 211. GCC WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 212. GCC WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. G7 WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 242. G7 WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 244. G7 WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 245. G7 WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. G7 WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. G7 WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. NATO WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 253. NATO WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 255. NATO WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 256. NATO WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. NATO WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. NATO WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)